Advertisement
The new Pharmacor report entitled Diabetic Complications: Retinopathy,Neuropathy, and Nephropathy finds that, over the next decade, treatment ofdiabetic complications will expand considerably beyond tight control of bloodpressure and glucose levels. Lucentis and ruboxistaurin will come the closestto achieving blockbuster status as treatments for diabetic complications inthe world's major pharmaceutical markets -- the United States, France,Germany, Italy, Spain, the United Kingdom and Japan. Additionally, althoughpromising drug classes with potential disease-modifying activity that includePKC inhibitors and aldose reductase inhibitors have suffered a decade ofsetbacks and disappointing efficacy data, the report finds that longer-termmarket growth will be driven by several of these novel therapies.
Advertisement
Therapies for the painful symptoms of diabetic neuropathy will continue todominate sales, and few patients suffering non-painful diabetic neuropathywill receive treatment until the launches of disease-modifying therapies nearthe midpoint of the 2006-2016 forecast period.
"The diabetic neuropathy market will experience growth during the secondhalf of our study period because of increasing use of Pfizer's antiepilepticdrug, Lyrica, and Eli Lilly's antidepressant Cymbalta, which are both approvedspecifically for the treatment of diabetic neuropathic pain," said Donny Wong,Ph.D., analyst at Decision Resources. "Longer term growth will also be drivenby the launch of novel disease-modifying therapies such asDainippon/Eisai/Kyorin's ranirestat and Sangamo Biosciences' SB-509."
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources
